# A Study to Assess The Relative Bioavailability of New Tablet Formulations of GSK1265744 in Healthy Adult Subjects

> **NCT02059031** · PHASE1 · COMPLETED · sponsor: **ViiV Healthcare** · enrollment: 24 (actual)

## Conditions studied

- Infection, Human Immunodeficiency Virus

## Interventions

- **DRUG:** GSK1265744 Reference formulation
- **DRUG:** GSK1265744 New formulation 1
- **DRUG:** GSK1265744 New formulation 2

## Key facts

- **NCT ID:** NCT02059031
- **Lead sponsor:** ViiV Healthcare
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2014-02
- **Primary completion:** 2014-06
- **Final completion:** 2014-06
- **Target enrollment:** 24 (ACTUAL)
- **Last updated:** 2014-07-16


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02059031

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02059031, "A Study to Assess The Relative Bioavailability of New Tablet Formulations of GSK1265744 in Healthy Adult Subjects". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT02059031. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*